Cargando…
Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients
Elevated B lymphocyte activating factor BAFF levels have been reported in multiple sclerosis (MS) patients; moreover, disease-modifying treatments (DMT) have shown to influence blood BAFF levels in MS patients, although the significance of these changes is still controversial. In addition, BAFF leve...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935889/ https://www.ncbi.nlm.nih.gov/pubmed/27383531 http://dx.doi.org/10.1038/srep29268 |
_version_ | 1782441476358144000 |
---|---|
author | Mameli, Giuseppe Cocco, Eleonora Frau, Jessica Arru, Giannina Caggiu, Elisa Marrosu, Maria Giovanna Sechi, Leonardo A. |
author_facet | Mameli, Giuseppe Cocco, Eleonora Frau, Jessica Arru, Giannina Caggiu, Elisa Marrosu, Maria Giovanna Sechi, Leonardo A. |
author_sort | Mameli, Giuseppe |
collection | PubMed |
description | Elevated B lymphocyte activating factor BAFF levels have been reported in multiple sclerosis (MS) patients; moreover, disease-modifying treatments (DMT) have shown to influence blood BAFF levels in MS patients, although the significance of these changes is still controversial. In addition, BAFF levels were reported increased during infectious diseases. In our study, we wanted to investigate on the serum BAFF concentrations correlated to the antibody response against Mycobacterium avium subspecies paratuberculosis (MAP), Epstein-Barr virus (EBV) and their human homologous epitopes in MS and in patients affected with other neurological diseases (OND), divided in Inflammatory Neurological Diseases (IND), Non Inflammatory Neurological Diseases (NIND) and Undetermined Neurological Diseases (UND), in comparison to healthy controls (HCs). Our results confirmed a statistically significant high BAFF levels in MS and IND patients in comparison to HCs but not NIND and UND patients. Interestingly, BAFF levels were inversely proportional to antibodies level against EBV and MAP peptides and the BAFF levels significantly decreased in MS patients after methylprednisolone therapy. These results implicate that lower circulating BAFF concentrations were present in MS patients with humoral response against MAP and EBV. In conclusion MS patients with no IgGs against EBV and MAP may support the hypothesis that elevated blood BAFF levels could be associated with a more stable disease. |
format | Online Article Text |
id | pubmed-4935889 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-49358892016-07-08 Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients Mameli, Giuseppe Cocco, Eleonora Frau, Jessica Arru, Giannina Caggiu, Elisa Marrosu, Maria Giovanna Sechi, Leonardo A. Sci Rep Article Elevated B lymphocyte activating factor BAFF levels have been reported in multiple sclerosis (MS) patients; moreover, disease-modifying treatments (DMT) have shown to influence blood BAFF levels in MS patients, although the significance of these changes is still controversial. In addition, BAFF levels were reported increased during infectious diseases. In our study, we wanted to investigate on the serum BAFF concentrations correlated to the antibody response against Mycobacterium avium subspecies paratuberculosis (MAP), Epstein-Barr virus (EBV) and their human homologous epitopes in MS and in patients affected with other neurological diseases (OND), divided in Inflammatory Neurological Diseases (IND), Non Inflammatory Neurological Diseases (NIND) and Undetermined Neurological Diseases (UND), in comparison to healthy controls (HCs). Our results confirmed a statistically significant high BAFF levels in MS and IND patients in comparison to HCs but not NIND and UND patients. Interestingly, BAFF levels were inversely proportional to antibodies level against EBV and MAP peptides and the BAFF levels significantly decreased in MS patients after methylprednisolone therapy. These results implicate that lower circulating BAFF concentrations were present in MS patients with humoral response against MAP and EBV. In conclusion MS patients with no IgGs against EBV and MAP may support the hypothesis that elevated blood BAFF levels could be associated with a more stable disease. Nature Publishing Group 2016-07-07 /pmc/articles/PMC4935889/ /pubmed/27383531 http://dx.doi.org/10.1038/srep29268 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Mameli, Giuseppe Cocco, Eleonora Frau, Jessica Arru, Giannina Caggiu, Elisa Marrosu, Maria Giovanna Sechi, Leonardo A. Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title_full | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title_fullStr | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title_full_unstemmed | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title_short | Serum BAFF levels, Methypredsinolone therapy, Epstein-Barr Virus and Mycobacterium avium subsp. paratuberculosis infection in Multiple Sclerosis patients |
title_sort | serum baff levels, methypredsinolone therapy, epstein-barr virus and mycobacterium avium subsp. paratuberculosis infection in multiple sclerosis patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935889/ https://www.ncbi.nlm.nih.gov/pubmed/27383531 http://dx.doi.org/10.1038/srep29268 |
work_keys_str_mv | AT mameligiuseppe serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT coccoeleonora serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT fraujessica serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT arrugiannina serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT caggiuelisa serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT marrosumariagiovanna serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients AT sechileonardoa serumbafflevelsmethypredsinolonetherapyepsteinbarrvirusandmycobacteriumaviumsubspparatuberculosisinfectioninmultiplesclerosispatients |